ATE312175T1 - Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel - Google Patents

Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel

Info

Publication number
ATE312175T1
ATE312175T1 AT95914227T AT95914227T ATE312175T1 AT E312175 T1 ATE312175 T1 AT E312175T1 AT 95914227 T AT95914227 T AT 95914227T AT 95914227 T AT95914227 T AT 95914227T AT E312175 T1 ATE312175 T1 AT E312175T1
Authority
AT
Austria
Prior art keywords
neurons
increase
survival rate
means usable
usable therefor
Prior art date
Application number
AT95914227T
Other languages
English (en)
Inventor
Graham Leslie Barrett
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE312175T1 publication Critical patent/ATE312175T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT95914227T 1993-10-18 1994-10-18 Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel ATE312175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM187093 1993-10-18
PCT/AU1994/000631 WO1995011253A1 (en) 1993-10-18 1994-10-18 A method for enhancing neurone survival and agents useful for same

Publications (1)

Publication Number Publication Date
ATE312175T1 true ATE312175T1 (de) 2005-12-15

Family

ID=3777280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914227T ATE312175T1 (de) 1993-10-18 1994-10-18 Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel

Country Status (7)

Country Link
US (2) US5837694A (de)
EP (2) EP1683863A3 (de)
JP (1) JP4281926B2 (de)
AT (1) ATE312175T1 (de)
CA (1) CA2174425A1 (de)
DE (1) DE69434569T2 (de)
WO (1) WO1995011253A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
WO2004031347A2 (en) * 2002-09-24 2004-04-15 Massachusetts Institute Of Technology Methods and compositions for soluble cpg15
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
US7556942B2 (en) * 2003-07-15 2009-07-07 Board Of Regents, The University Of Texas System Tumor suppressor designated Hippo
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US20050187175A1 (en) * 2003-09-30 2005-08-25 Elly Nedivi Methods and compositions for CPG15-2
WO2007095113A2 (en) * 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006008C (en) * 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
CA2143945A1 (en) * 1992-09-11 1994-03-31 Daniel Djakiew A method for the detection and treatment of prostate disease
AU4983693A (en) 1992-09-11 1994-04-12 Nippon Kinzoku Co. Ltd. Refined magnesium material and process for producing the same

Also Published As

Publication number Publication date
EP0724589B1 (de) 2005-12-07
JP4281926B2 (ja) 2009-06-17
DE69434569T2 (de) 2006-08-24
CA2174425A1 (en) 1995-04-27
EP0724589A1 (de) 1996-08-07
US5837694A (en) 1998-11-17
US6174869B1 (en) 2001-01-16
JPH09503512A (ja) 1997-04-08
EP1683863A2 (de) 2006-07-26
EP0724589A4 (de) 1998-09-16
WO1995011253A1 (en) 1995-04-27
EP1683863A3 (de) 2006-08-02
DE69434569D1 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
DE69636147D1 (de) Verfahren zur herstellung von phosphorothioat-oligomeren
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE3886254D1 (de) Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat.
BR9206026A (pt) Análogo de oligonucleotídio, processo para modular a produção ou atividade de uma proteína em um organismo, e, processo para proteger um análogo de oligonucleotídio ou nucleosídio bifuncional
FI971955A7 (fi) Dopamineeristen solujen indusointi in vitro
ATE154947T1 (de) Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
DE69434569D1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
DE69628864D1 (de) Invertierte chimäre und hybrid-oligonukleotide
DE69435218D1 (de) Regulation der Genexpression von bcl-2
ATE161039T1 (de) Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE3861352D1 (de) Hydrokrackverfahren von kohlenwasserstoffen und vorrichtung zur ausfuehrung des verfahrens.
ATE259652T1 (de) Neuronale verwendungen des bmp-11
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
IL160422A0 (en) Bv8 nucleic acids and polypeptides with mitogenic activity
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE59603224D1 (de) Verfahren und vorrichtung zur herstellung von hochviskosen oder hochstabilisierten, reaktionsstabilen polyamiden und zur kontinuierlichen entmonomerisierung von polyamiden
DE3865794D1 (de) Hydroraffinationskatalysator, ausgehend von hydrogelen, verfahren zur herstellung und verwendung.
IT1213100B (it) La produzione di prodotti sessuali impiego di sostanze stimolanti per da mammiferi,adatti per la fecondazione naturale ed artificiale e sostanze relative
ATE348589T1 (de) Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten
DE69414375D1 (de) Verfahren zur herstellung von 1,1,1,2,2-pentafluoroethan, verfahren zur herstellung von 2,2-dichloro-1,1,1-trifluoroethan und verfahren zur reinigung von 1,1,1,2,2-pentafluoroethan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties